GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theravance Biopharma Inc (NAS:TBPH) » Definitions » Ending Cash Position

TBPH (Theravance Biopharma) Ending Cash Position : $24.21 Mil (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Theravance Biopharma Ending Cash Position?

Theravance Biopharma's Ending Cash Position for the quarter that ended in Sep. 2024 was $24.21 Mil.

Theravance Biopharma's quarterly Ending Cash Position declined from Mar. 2024 ($54.67 Mil) to Jun. 2024 ($47.18 Mil) and declined from Jun. 2024 ($47.18 Mil) to Sep. 2024 ($24.21 Mil).

Theravance Biopharma's annual Ending Cash Position increased from Dec. 2021 ($90.80 Mil) to Dec. 2022 ($299.01 Mil) but then declined from Dec. 2022 ($299.01 Mil) to Dec. 2023 ($40.38 Mil).

Theravance Biopharma Ending Cash Position Historical Data

The historical data trend for Theravance Biopharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theravance Biopharma Ending Cash Position Chart

Theravance Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 58.90 82.30 90.80 299.01 40.38

Theravance Biopharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 72.52 40.38 54.67 47.18 24.21

Theravance Biopharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Theravance Biopharma's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=299.008+-258.627
=40.38

Theravance Biopharma's Ending Cash Position for the quarter that ended in Sep. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=47.181+-22.967
=24.21

Theravance Biopharma Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Theravance Biopharma's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Theravance Biopharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theravance Biopharma Inc (NAS:TBPH) » Definitions » Ending Cash Position
Comparable Companies
TYRA ELVN SVRA ARCT ALPN VERA TVTX ZYME AUTL PHAT OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
0TB:Germany
Address
Ugland House, South Church Street, George Town, PO Box 309, Grand Cayman, CYM, KY1-1104
Website
https://www.theravance.com
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Executives
Rhonda Farnum officer: SVP, Comm & Medical Affairs 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Eli Samaha 10 percent owner ONE WORLD TRADE CENTER, FLOOR 65, NEW YORK NY 10007
Richard A Graham officer: SVP, Development 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Kelly James Connor director 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Susannah Gray director 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Brett A. Grimaud officer: SVP, Gen Counsel and Secretary 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Aziz Sawaf officer: SVP & Chief Financial Officer 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Rick E Winningham director, officer: Chief Executive Officer 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Andrew A. Hindman officer: SVP, Chief Financial Officer C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Weiss Asset Management Lp 10 percent owner 222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116
Andrew M Weiss 10 percent owner 222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116
Wam Gp Llc 10 percent owner 222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116
Philip D Worboys officer: SVP, Translational Science 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Brett K Haumann officer: VP-Clinical Develop. 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Deepika Pakianathan director 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402